Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Dr Laura Burga

PositionResearch Fellow
DepartmentDepartment of Microbiology and Immunology
QualificationsPhD
Research summaryStructural biology, viral pathogenesis and molecular virology

Research

Working with Dr Mihnea Bostina

Publications

Miles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017). Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. Journal of Clinical Investigation. Advance online publication. doi: 10.1172/jci93472

Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., … Burga, L. N., … Vander Heiden, M. G. (2013). PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell, 155, 397-409. doi: 10.1016/j.cell.2013.09.025

Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmaña, J., … Wulf, G. M. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discovery, 2(11), 1048-1063. doi: 10.1158/2159-8290.CD-11-0336

Burga, L. N., Tung, N. M., Troyan, S. L., Bostina, M., Konstantinopoulos, P. A., Fountzilas, H., … Wulf, G. M. (2009). Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Research, 69(4), 1273-1278. doi: 10.1158/0008-5472.can-08-2954

Journal - Research Article

Miles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017). Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. Journal of Clinical Investigation. Advance online publication. doi: 10.1172/jci93472

Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., … Burga, L. N., … Vander Heiden, M. G. (2013). PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell, 155, 397-409. doi: 10.1016/j.cell.2013.09.025

Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmaña, J., … Wulf, G. M. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discovery, 2(11), 1048-1063. doi: 10.1158/2159-8290.CD-11-0336

Burga, L. N., Tung, N. M., Troyan, S. L., Bostina, M., Konstantinopoulos, P. A., Fountzilas, H., … Wulf, G. M. (2009). Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Research, 69(4), 1273-1278. doi: 10.1158/0008-5472.can-08-2954

More publications...